NewAmsterdam Pharma Warrant
NAMSW
21 hedge funds and large institutions have $4.53M invested in NewAmsterdam Pharma Warrant in 2022 Q4 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$412K |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$274K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$235K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$123K |
| 5 |
ETH
Exos TFP Holdings
New York
|
+$113K |
Top Sellers
NAMSW Hedge Fund Activity: Q4 2022 in Review
21 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma Warrant (NAMSW) for Q4 2022, worth a combined $4.53M.
Buyers outnumbered sellers: 21 funds opened new NAMSW positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $412K.
- 21 institutional investors held NewAmsterdam Pharma Warrant (NAMSW) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $4.53M of NewAmsterdam Pharma Warrant stock for Q4 2022.
- 21 funds opened new NewAmsterdam Pharma Warrant positions in Q4 2022 and 0 closed out, a net change of +21 holders.
- The largest NewAmsterdam Pharma Warrant buyer in Q4 2022 was Frazier Life Sciences Management, an estimated $412K added.
Based on aggregated 13F filings for Q4 2022.